Health Economics›T-cell acute lymphoblastic leukemia›Consolidation after upfront therapy

Consolidation after upfront therapy

T-cell acute lymphoblastic leukemia · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Etoposide and TBI, then allo HSCT Variant #03 Partial	—	R 6 770	—	—	—	~1	~R 6 770 indirect	—

1 of 1 regimen shown